BIIB Biogen Inc.

250.80
-2.17  -1%
Previous Close 252.97
Open 252.59
Price To book 4.67
Market Cap 53.20B
Shares 212,115,000
Volume 833,069
Short Ratio 1.52
Av. Daily Volume 1,552,910

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 ready to be initiated. Acquired from Remedy Pharmaceuticals May 15, 2017.
CIRARA (intravenous glyburide)
Ischemic stroke
Phase 2 initiated April 2017.
BMS-986168 - Anti Tau
Progressive supranuclear palsy (PSP)
Phase 2 planned.
BMS-986168 - Anti Tau
Alzheimer’s disease
Phase 3 dosing commenced December 2016.
Elenbecestat (E2609) - (MissionAD2)
Alzheimer’s disease
Phase 3 enrollment to be completed mid-2018.
Aducanumab (Aβ mAb) - EMERGE
Alzheimer’s disease
Phase 3 to be initiated in 2018.
BIIB074 (Nav1.7 inhibitor)
Trigeminal Neuralgia
Phase 3 dosing commenced December 2016.
Elenbecestat (E2609) - (MissionAD1)
Alzheimer’s disease
Phase 2b to be initiated 4Q 2017.
Opicinumab (anti-LINGO)
Multiple sclerosis (MS)
Phase 3 enrollment to be completed mid-2018.
Aducanumab (Aβ mAb) - ENGAGE
Alzheimer’s disease
Phase 2b enrollment to be completed 2017.
Natalizumab (α4-integrin inhibitor)
Acute ischemic stroke
Phase 2 initiated 2016. Data due in 2018.
Raxatrigine - BIIB074 (Nav1.7 inhibitor)
Painful Lumbosacral Radiculopathy (PLSR)
Phase 2 topline data showed no statistically significant treatment effect for primary and secondary endpoints - 1Q 2016.
Raxatrigine - BIIB074 (Nav1.7 inhibitor)
Erythromelagia
Phase 2 ongoing.
Dapirolizumab pegol (anti-CD40L)
Lupus
Phase 2 dosing commenced October 2016.
BIIB059 (anti-BDCA2)
Lupus
Phase 2 data due by the end of 2017.
BAN2401 (Aβ mAb)
Alzheimer’s disease
Phase 2 to be completed 2017.
BG00011 (STX-100)
Idiopathic pulmonary fibrosis (IPF)
Phase 1/2 data due mid-2017.
XLRS Gene Therapy
X-linked retinoschisis (XLRS)

Latest News

  1. Which Biotechs Benefit Most Under Trump's Tax Reform Vision?
  2. Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer
  3. Biogen (BIIB) Down 9.5% Since Earnings Report: Can It Rebound?
  4. ​Another top Biogen executive stepping down
  5. Short Sellers Raise the Stakes in Major Biotechs
  6. Biogen's Fampyra Conditional Approval Converted to Standard
  7. Deadly brain infection in German MS patient prompts Roche investigation
  8. Biogen Spinoff Bioverativ Squares Off With Roche After $400 Million Buy
  9. Roche investigating case of patient illness after taking MS drug
  10. Biogen’s FAMPYRA® Granted Standard Marketing Authorization in European Union for Improvement of Walking in People with MS
  11. Celgene Stock Rises Premarket on Positive Late-Stage Test Results for Multiple Sclerosis Treatment
  12. Why Long-Term Investors Should Prefer Celgene Over Biogen
  13. Amgen, Gilead, Biogen Won't Lead The Biotech Boom — So Who Will?
  14. 5 Reasons Big Biotech Could Gain 25%-30%
  15. Why Stay Bullish On Gilead
  16. Biogen has acquired Remedy Pharma's stroke medication for $120 mln
  17. Biogen Acquires Remedy Pharmaceuticals’ Late-Stage Drug CIRARA™
  18. Biogen to Present at the Bernstein 33rd Annual Strategic Decisions Conference
  19. Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal
  20. This Fund’s Picks Gained 200% In A Year And Why No One Knows About It